PHASE III CLINICAL STUDY RESULTS OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2-P

Contact Us

Products

• Core Product
• API
• Formulation
• Quality Assurance

Science

• R&D
• Solutions

About Us

• Who are we
• Our history
• Main production base
• Governance and Leadership